

CURRICULUM VITAE

August 30th 2019

NAME: RICHARD E CLARK

ADDRESS: University Department of Haematology
2nd Floor, Duncan Building
Royal Liverpool University Hospital
Prescot Street
Liverpool L7 8XP

CONTACT DETAILS: 0151-794-9818 (Tel): 0151-706-5810 (Fax)
E-mail: clarkre@liverpool.ac.uk

PRESENT POST: Professor of Haematology, University of Liverpool; Honorary Consultant Haematologist, Royal Liverpool University Hospital.

HIGHER EDUCATION: Churchill College, Cambridge University (1972-5).
Westminster Medical School, London (1975-8).

QUALIFICATIONS:

Degrees:

1975 Bachelor of Arts (Hons), Medical Science & Mammalian Physiology (University of Cambridge)
1978 Bachelor of Medicine and Surgery (MB, BS) (University of London)
1982 Master of Arts (MA) (University of Cambridge)
1986 Doctor of Medicine (MD) (University of London)

Diplomas:

1981 Membership of Royal College of Physicians (MRCP); Fellow 1994-2013
1987 Membership of Royal College of Pathologists (MRCPATH); Fellow 1996-2018

Accreditation in Haematology by JCHMT in June 1987.

Present Post:

Professor of Haematology, University of Liverpool (Senior Lecturer 1990–8; Reader 1998-2004).
Honorary Consultant Haematologist, Royal Liverpool University Hospital Trust, 1990-present.
Director of the Mersey Regional Bone Marrow Transplant (BMT) programme 1990-2014.

ADMINISTRATIVE EXPERIENCE (national/international only):

Medical Research Council (MRC) /National Cancer Research Institute (NCRI)

Member, MRC Working Party for Leukaemia in Adults 1991-2013 (renamed in 2002 as the (Adult) Haematological Oncology Group of the NCRI), which is responsible for the design and monitoring of clinical trials in adult leukaemia and related diseases. I have a specialist interest in myeloid malignancy, especially chronic myeloid leukaemia (CML).

From 2006-13 I chaired the NCRI CML subgroup (member of this subgroup since 1996 and continuing).

Member, NCRI acute myeloid leukaemia (AML) subgroup since 2003.

Clinical trials experience

Member, study management group for the national phase III NCRI CML studies SPIRIT1 and 2.

National Chief Investigator for (all NCRN badged) the following trials of my own design:

- 1) DESTINY, a trial of de-escalation/stopping treatment in CML (~completed).
- 2) PHANTASTIC, a trial of first line plerixafor for stem cell mobilisation (completed)
- 3) EPIC CML and EPIC Healthy, vaccine trials in CML and healthy donors respectively (both completed)

Chair, Data Monitoring Committee for MyeChild, the current international trial for AML in children (ongoing; opened 2016).

Chair, Data Monitoring Committee for AML 18 and 19, the current national Phase III NCRI trials in older and younger adults respectively with AML (ongoing; opened 2015).

Clinical Co-ordinator for AML17, an NCRI trial for younger AML (recruited 2008-14).

Co-granther (led by Prof. Holyoake, Glasgow) on an MRC award to us and 2 other sites to support CHOICES, a clinical trial of autophagy inhibition in imatinib-resistant CML (completed).

Grants committees

Member of the Leukaemia Research Fund (now Bloodwise) Clinical Panel from 1999-2008, to advise on the funding of grant applications for clinical studies in haematological malignancy.

Member, Cancer Research UK Clinical Trials Awards Advisory Committee (CTAAC) 2007-10.

Member, grants committee for transplant studies for Leuka (national leukaemia charity) 2016-18.

International administrative work

Member, External Advisory Committee on Cancer, University of Bordeaux, France (2013-15)

Member, External Advisory Committee for the Ludwig Boltzmann Institute, University of Vienna, Austria (2017-18)

Member, International Advisory committee on cardiovascular safety of nilotinib in CML, Novartis Pharmaceuticals (2013-15).

Chair, European Haematology Association Scientific Working Group on CML, in 2014.

Co-chair, European LeukaemiaNet Committee on side effects of CML therapy (2013-16).

Editorial work

Member, Editorial Board, Leukemia and Lymphoma, 2001-2006.

Member, Editorial Board, Leukaemia Research, 2004-2013 ('Reviewer of the year' 2011).

Other

Invited representative of British Society for Haematology/ RCPATH, 2008 -12, for National Institute of Clinical Excellence (NICE) appraisal of dasatinib and nilotinib in CML.